Bisphosphonates (BPs) are an important class of drugs, useful in the treatment of some metabolic and oncologic skeletal diseases. BPs have shown a sure effectiveness in the treatment and in the palliative care of such pathologies; on the other hand, an avascular osteonecrosis of the jaws (B-ONJ = Bisphosphonate OsteoNecrosis of the Jaw) has recently been reported as an adverse effect not only of BP intravenous infusions, but also of their prolonged oral administration. B-ONJ normally follows a dental extraction or other surgical procedure in the oral cavity, but it also can develop spontaneously. In the latter case, some systemic risk factors, such as comorbidities and co-therapies or jaw anatomical conditions, can play a leading role in the onset of this pathologic condition. B-ONJ is an uncommon but potentially serious complication of BP therapy that can gravely affect the patient's quality of life, producing significant morbidity. To date, no therapies are completely effective and predictable in the treatment of B-ONJ, therefore prevention should be strongly promoted by sharing knowledge in the involved medical community.
MarxRESternDS. Biopsy principles and techniques. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment. 2002. Chicago: Quintessence: 36–38
2.
DeardenWF. Fragilitas ossium amongst workers in Lucifer match factories. Br Med J1899; 2:270–1.
3.
RussellRG. Bisphosphonates: From bench to bedside. Ann NY Acad Sci2006; 1068:367–401.
4.
RoelofsAJThompsonKGordonSRogersMJ. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res2006; 12:6222s–6230s.
5.
FrithJCMönkkönenJBlackburnGMRussellRGRogersMJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res1997; 12:1358–67.
6.
GhoneimaAAAllamESZuntSLWindsorLJ. Bisphosphonates treatment and orthodontic considerations. Orthod Craniofac Res2010; 13:1–10.
7.
PavlosNJXuJRiedelD. Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol2005; 25:5253–69.
8.
FujitaHUtsumiTMuranakaSOginoTYanoHAkiyamaJYasudaTUtsumiK. Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol2005; 69:1773–84.
9.
Van BeekERLöwikCWPapapoulosSE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone2002; 30:64–70.
10.
IguchiTMiyakawaYYamamotoKKizakiMIkedaY. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal2003; 15:719–27.
11.
TanakaTTatsunoIUchidaD. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci2000; 20:2852–9.
12.
MerrellMAWakchoureSLehenkariPPHarrisKWSelanderKS. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol2007; 570:27–37.
13.
VirtanenSSVäänänenHKHärkönenPLLakkakorpiPT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res2002; 62:2708–14.
14.
SuriSMönkkönenJTaskinenMPesonenJBlankMAPhippsRJRogersMJ. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity. Bone2001; 29:336–43.
15.
ScavelliCDi PietroGCirulliT. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther2007; 6:3256–62.
16.
SantiniDVincenziBGalluzzoS. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res2007; 13:4482–6.
17.
GiraudoEInoueMHanahanD. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest2004; 114:623–33.
18.
GreenJRMüllerKJaeggiKA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res1994; 9:745–51.
19.
WangJGoodgerNMPogrelMA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg2003; 61:1104–7.
20.
MarxRE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg2003; 61:1115–17.
21.
RuggieroSLMehrotraBRosenbergTJEngroffSL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg2004; 62:527–34.
22.
FilleulOCrompotESaussezS. Bisphosphonate-induced osteonecrosis of the jaw: A review of 2,400 patient cases. J Cancer Res Clin Oncol2010; 136:1117–24.
23.
BertoldoFSantiniDLo CascioV. Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle. Nat Clin Pract Oncol2007; 4:711–21.
24.
ChristodoulouCPervenaAKlouvasG. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology2009; 76:209–11.
25.
SenelFCDumanMKMuciECankayaMPampuAAErsozSGunhanO. Jaw bone changes in rats after treatment with zoledronate and Pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2010; 109:385–91.
26.
LehrerSMontazemARamanathanLPessin-MinsleyMPfailJStockRGKoganR. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg2009; 67:159–6
27.
KumarSKGorurASchaudinnCShulerCFCostertonJWSedghizadehPP. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep2010; 8:40–48.
28.
MavrokokkiTChengASteinBGossA. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg2007; 65:415–23.
29.
KhoslaSBurrDCauleyJ; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res2007; 22:1479–91.
30.
MiglioratiCASiegelMAEltingLS. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol2006; 7(6):508–54.
31.
MehrotraBRuggieroS. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program2006; 515:356–60.
32.
ChiandussiSBiasottoMDoreFCavalliFCovaMADi LenardaR. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol.2006; 35:236–43.
33.
RuggieroSGralowJMarxRE. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract2006; 2:7–14.
34.
NociniPFSaiaGBettiniGRagazzoMBlandamuraSChiariniLBedogni. A Vascularized fibula flap reconstruction of the mandible in bisphosphonate-related osteonecrosis. Eur J Surg Oncol2009; 35:373–9.
35.
PastoreDGrecoMPetragalloVAPassarellaS. Increase in <–H+/e- ratio of the cytochrome c oxidase reaction in mitochondria irradiated with helium-neon laser. Biochem Mol Biol Int1994; 34:817–26.
36.
KaruTPyatibratLKalendoG. Irradiation with He-Ne laser increases ATP level in cells cultivated in vitro. J Photochem Photobiol B1995; 27:219–23.
37.
AgrilloAUngariCFiliaciFPriorePIannettiG. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg2007; 18:1071–5.
38.
VescoviPMerigoEManfrediMMeletiMFornainiCBonaniniMRoccaJPNammourS. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: Clinical experience in 28 cases. Photomed Laser Surg2008; 26:37–46
39.
ScolettaMArduinoPGReggioLDalmassoPMozzatiM. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: Preliminary results of a prospective study. Photomed Laser Surg2010; 28:179–84.
40.
CuriMMCossolinGSKogaDHAraújoSRFeherOdos SantosMOZardettoC. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases. J Oral Maxillofac Surg2007; 65:349–55.
